Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13904007 | 0.93 | PRKCA (0.45) | LMNAMMP12MMP9TNFPRKCA | |
| SCHEMBL6044028 | 0.92 | LMNA (0.50) | LMNAKMT2AMMP12MMP9POLB | |
| SCHEMBL23627104 | 0.87 | LMNA (0.45) | LMNAKMT2AMMP12MMP9POLB | |
| SCHEMBL30608556 | 0.87 | LMNA (0.44) | LMNAKMT2AMMP12MMP9POLB | |
| SCHEMBL23626685 | 0.87 | LMNA (0.44) | LMNAKMT2AMMP12MMP9POLB | |
| SCHEMBL13163903 | 0.84 | PRKCA (0.47) | LMNAMMP12MMP9TNFPRKCA | |
| SCHEMBL14402257 | 0.82 | LMNA (0.42) | LMNAKMT2ATNFPRKCAAKT1 | |
| SCHEMBL16244990 | 0.81 | LMNA (0.54) | LMNAKMT2AMMP12MMP9POLB | |
| SCHEMBL9338908 | 0.81 | LMNA (0.46) | LMNAKMT2AMMP12MMP9POLB | |
| SCHEMBL23627066 | 0.80 | LMNA (0.41) | LMNAKMT2AMMP12MMP9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-01-18 | — | — | US | disclosed |
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779592-B2 | Inhibition of NGLY1 for the treatment of cancer | NGLY1, GALNT1, GALNT10 | LMNA 2369/4885KMT2A 4129/4885MMP12 4233/4885 |
| US-20240016828-A1 | INHIBITION OF NGLY1 FOR THE TREATMENT OF CANCER | NGLY1, GALNT1, GALNT10 | LMNA 2401/4885KMT2A 3992/4885MMP12 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.